The executive of the pharmaceutical company GSK must choose whether to integrate the newly acquired biotechnology firm, Sirtris. Moncef Slaoui, Global Head of GSK R & D, acquisition of Sirtris stood to gain access to its potentially revolutionary science. Slaoui must balance the need to recoup the cost of the shares after the payment of two times the award for Sirtris with his desire to keep Christoph Westphal, Sirtris co-founder and CEO, and other key people in the company. His desire to protect Sirtris by GSK and the size of the bureaucracy is the period when GSK began major changes in their R & D organizations, which are aimed at decentralization and the externalization of R & D, as well as reconstruction of the process of resource allocation for parallel more venture capital-based model. The case also explores the views of Christoph Westphal early integration issues and the impact of GSK has on Sirtris. Can be used in conjunction with the individual case-oriented business model Sirtris website. "Hide
by Toby Stuart, James Weber Source: Harvard Business School 10 pages. Publication Date: 04 Oct 2012. Prod. #: 813028-PDF-ENG
Related Case Solutions & Analyses:
The IPO of Agricultural Bank of China (ABC) (A)
The American Repertory Theater
Leading Change at Simmons (B)
China Goes Global: The New Taste of Chinese Companies for Foreign Assets
Dividend Policy at Linear Technology
2001 Crisis in Argentina: An IMF-Sponsored Default (B)
Online Securities Trading in Japan
Challenge the Boss or Stand Down
Fund Development and Financial Management for Non-profit organizations
Bran capital: outback steak house
